This is a non-promotional communication intended to facilitate transparent scientific exchange regarding developments in medical research and disease management amongst U.S. healthcare professionals. The content in the abstract and publication accessible through the buttons below includes scientific information about investigational medicines, including ozekibart (INBRX-109). Ozekibart (INBRX-109) is an investigational medicine whose efficacy and safety profile have not been established. It has not been approved by the U.S. FDA or other health authority for any use.

By clicking on one of the buttons below, you confirm that you are a U.S. healthcare professional and acknowledge you have read and understood this message and are requesting access to the scientific material.

CTOS 2025 Abstract
CTOS Oral Presentation
BSG 2026 Oral Presentation